Boston Scientific Production Of NIR-On-Ranger Stent With SOX On Hold
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is ramping up produciton of its NIR Primo coronary stent - also known as the NIR-On-Ranger without the SOX securing system - after temporarily ceasing production of the system with SOX due to a higher than anticipated balloon failure rate, the firm says.
You may also be interested in...
Boston Scientific Liberty Stent Groomed To Face Next-Gen Cobalt Competitors
Boston Scientific will enroll approximately 400 patients in an ongoing clinical trial to support a PMA supplement for the firm's Taxus Liberty stent platform
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”